RESEARCH TRIANGLE PARK, NC, Aug. 24, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq: SNCE) today announced new patient relationship management and contact center technologies that improve patient engagement. Registration conversion rate.

Science 37’s new patient relationship management platform significantly streamlines media planning, placement, reporting and patient communication, enabling faster and more qualified patient recruitment for clinical trials. The platform will also curate content that can be used to improve engagement among Science 37’s existing patient community.

Science 37’s new contact center technology enables near-real-time interaction via a variety of communication channels between eligible patients and remote study coordinators after expressing research interest and requesting participation Make every opportunity available to eligible patients. sign up.

Science 37 Chief Delivery Officer Darcy Forman said: , is on a mission to provide universal access to anyone, anywhere. “

Patient enrollment in clinical studies is a major factor in clinical trial delays, representing a staggering 80% of all trials.¹This is not surprising given that far fewer than 8% of patients are admitted to clinical trials.² Under the traditional site-based model, which inherently creates geographic boundaries and poses fundamental access challenges.

“Study sponsors often deploy multi-channel approaches to direct patients from outside the investigator’s clinic to brick-and-mortar sites, but traditional sites require these referrals to enter the study. I don’t have any track record to register, I succeeded,” continued Foreman. “Science 37’s registration model is designed entirely with the idea that no patient should be left behind.”

About Science 37
The mission of Science 37 Holdings, Inc. (Nasdaq: SNCE) is to enable universal access to clinical research. This makes it easy for patients and providers to participate from anywhere, accelerating the development of therapies that impact patients’ lives. As a pioneer in distributed clinical trials, the Science 37l operating system (OS) is a full-stack, end-to-end technology platform and platform for patient communities, telemedicine researchers, mobile nurses, remote coordinators, provider communities, data and devices. . Science 37 OS is configurable to enable virtually any study type, with industry-leading workflow orchestration, evidence generation and data harmonization for up to 21x faster enrollment and 28% higher retention , and allow for a three-fold more diverse patient population. For more information, see: https://www.science37.com.

sauce
¹ Science 37, 2022 Brand Benchmark Study.
² Unger, JM, Vaidya, R., Hershman, DL, Miniasian, LM, Fleury, M.: “A systematic review of the magnitude of structural, clinical, physician, and patient barriers to cancer clinical trial participation. and meta-analysis”; Journal of the National Cancer Institute, Vol. 111, Issue 3, March 2019.

Cautionary Note Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws, including statements regarding the products Science 37 offers, its sales pipeline and the markets in which it operates. These forward-looking statements generally include statements such as “believe,” “forecast,” “anticipate,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” ‘, ‘planned’, ‘may’, ‘should’, ‘would’, ‘would’, ‘would’, ‘will continue’, ‘probably will result’. Forward-looking statements are predictions, forecasts and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. A number of factors could cause actual future events to differ materially from the forward-looking statements in this press release. This includes, but is not limited to: (i) the ability to maintain his Nasdaq listing of Science 37 securities; and (ii) price volatility. This includes changes in the competitive and highly regulated industries in which Science 37 operates, fluctuations in operating results among competitors, changes in laws and regulations affecting Science 37’s business, and changes in our capital structure. changes in Science 37’s securities due to a variety of factors, including changes; (iii) our ability to execute our business plans, forecasts and other expectations and to identify and realize additional opportunities; and (iv) Science 37’s ability to achieve profitability. (v) the risk that Science 37 will be required to raise additional funds; capital to carry out its business plans may not be available on acceptable terms or at all; (vi) potential adverse effects of the ongoing global COVID-19 pandemic; The preceding list of factors is not exhaustive. The aforementioned factors and other risks and uncertainties set forth in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission. Certainty must be considered carefully (“SEC”) and in other documents Science 37 files with the SEC from time to time. These filings identify and address other important risks and uncertainties that could cause actual events or results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on forward-looking statements. Science 37 undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as provided below. required by law. Science 37 does not warrant that Science 37 will achieve its expectations.

Media inquiries:
Drew Bastos
Science 37
PR@science37.com

Investor Relations:
caroline paul
Science 37 // Gilmartin
Investors@science37.com